Background: Cirrhosis is a progressive liver disease with high mortality and frequent complications, notably acute kidney injury (AKI), which occurs in up to 50% of hospitalized patients and worsens outcomes. AKI stems from complex hemodynamic, inflammatory, and metabolic changes, making early detection essential. Many predictive tools lack accuracy, interpretability, and alignment with intensive care unit (ICU) workflows. This study developed an interpretable machine learning model for early AKI prediction in critically ill patients with cirrhosis. Methods: We conducted a retrospective analysis of the MIMIC-IV v2.2 database, identifying 1240 adult ICU patients with cirrhosis and excluding those with ICU stays under 48 hours or missing key data. Laboratory and physiological variables from the first 48 hours were extracted. The pipeline included preprocessing, missingness filtering, LASSO feature selection, and SMOTE class balancing. Six algorithms-LightGBM, CatBoost, XGBoost, logistic regression, naive Bayes, and neural networks-were trained and evaluated using AUROC, accuracy, F1-score, sensitivity, specificity, and predictive values. Results: LightGBM achieved the best performance (AUROC 0.808, 95% CI 0.741-0.856; accuracy 0.704; NPV 0.911). Key predictors included prolonged partial thromboplastin time, absence of outside-facility 20G placement, low pH, and altered pO2, consistent with known cirrhosis-AKI mechanisms and suggesting actionable targets. Conclusion: The LightGBM-based model enables accurate early AKI risk stratification in ICU patients with cirrhosis using routine clinical variables. Its high negative predictive value supports safe de-escalation for low-risk patients, and interpretability fosters clinician trust and targeted prevention. External validation and integration into electronic health record systems are warranted.

Background: Vancomycin, a key antibiotic for severe Gram-positive infections in ICUs, poses a high nephrotoxicity risk. Early prediction of kidney injury in critically ill patients is challenging. This study aimed to develop a machine learning model to predict vancomycin-related creatinine elevation using routine ICU data. Methods: We analyzed 10,288 ICU patients (aged 18-80) from the MIMIC-IV database who received vancomycin. Kidney injury was defined by KDIGO criteria (creatinine rise >=0.3 mg/dL within 48h or >=50% within 7d). Features were selected via SelectKBest (top 30) and Random Forest ranking (final 15). Six algorithms were tested with 5-fold cross-validation. Interpretability was evaluated using SHAP, Accumulated Local Effects (ALE), and Bayesian posterior sampling. Results: Of 10,288 patients, 2,903 (28.2%) developed creatinine elevation. CatBoost performed best (AUROC 0.818 [95% CI: 0.801-0.834], sensitivity 0.800, specificity 0.681, negative predictive value 0.900). Key predictors were phosphate, total bilirubin, magnesium, Charlson index, and APSIII. SHAP confirmed phosphate as a major risk factor. ALE showed dose-response patterns. Bayesian analysis estimated mean risk 60.5% (95% credible interval: 16.8-89.4%) in high-risk cases. Conclusions: This machine learning model predicts vancomycin-associated creatinine elevation from routine ICU data with strong accuracy and interpretability, enabling early risk detection and supporting timely interventions in critical care.